CIK 0001023024 · Large accelerated filer
ANI PHARMACEUTICALS INC
Sign in to watch- Ticker
- ANIP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 582301143
- Phone
- 6097591810
- Business address
- 104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, NJ, 08540
- Former names
- BIOSANTE PHARMACEUTICALS INC, BEN ABRAHAM TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,939,756
- in 9 filings, $1.9M under 10b5-1 plans
Net −$1,939,756. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-01 | Gassert Chad SVP - CORP. DEV. & STRATEGY | Sale 10b5-1 | −20,000 | $63.44 | $1.3M | 193,226 |
| 2024-06-21 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −20,000 | $58.90 | $1.2M | 682,620 |
| 2024-06-20 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −11,447 | $59.86 | $685K | 702,620 |
| 2024-06-18 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −10,607 | $60.76 | $644K | 714,067 |
| 2024-06-17 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −7,946 | $61.41 | $488K | 724,674 |
| 2024-06-13 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 | −250 | $63.80 | $16K | 59,231 |
| 2024-06-07 | Marken James G. SVP OPS & PROD DEV | Option exercise | +7,250 | $49.51 | $359K | 123,616 |
| 2024-06-07 | Marken James G. SVP OPS & PROD DEV | Option exercise | +5,300 | $57.06 | $302K | 128,916 |
| 2024-06-07 | Marken James G. SVP OPS & PROD DEV | Shares withheld for taxes | −11,087 | $67.70 | $751K | 117,829 |
| 2024-06-07 | Marken James G. SVP OPS & PROD DEV | Option exercise · Stock Option (right to buy) | −7,250 | $49.51 | $359K | 0 |
| 2024-06-07 | Marken James G. SVP OPS & PROD DEV | Option exercise · Stock Option (right to buy) | −5,300 | $57.06 | $302K | 0 |
| 2024-06-05 | Gutwerg Ori SVP, GENERICS | Sale | −2,985 | $67.00 | $200K | 77,227 |
| 2024-06-04 | CAREY STEPHEN P. SVP & CFO | Sale | −5,000 | $63.58 | $318K | 161,968 |
| 2024-06-03 | Gassert Chad SVP - CORP. DEV. & STRATEGY | Sale 10b5-1 | −20,000 | $64.41 | $1.3M | 213,226 |
| 2024-05-21 | Thoma Jeanne Director | Grant or award | +4,410 | 40,609 | ||
| 2024-05-21 | Leonard Matthew J Director | Grant or award | +4,410 | 11,993 | ||
| 2024-05-21 | Walsh Patrick D Director | Grant or award | +4,410 | 74,712 | ||
| 2024-05-21 | Pera Antonio R Director | Grant or award | +4,410 | 31,037 | ||
| 2024-05-21 | TANNENBAUM RENEE P Director | Grant or award | +4,410 | 22,621 | ||
| 2024-05-21 | HAUGHEY THOMAS Director | Grant or award | +4,410 | 51,526 |
Page 12 of 23 · 442 trades